medsci-skills 4.1.0

package/skills/write-paper/references/journal_profiles/JNIS.md

@@ -0,0 +1,227 @@
+# Journal Profile: Journal of NeuroInterventional Surgery (JNIS)
+
+## Basic Information
+
+- **Publisher:** BMJ Publishing Group
+- **Society:** Society of NeuroInterventional Surgery (SNIS)
+- **Frequency:** Monthly (12 issues/year)
+- **Scope:** Endovascular and surgical neurointervention — acute ischemic stroke thrombectomy, intracranial aneurysm treatment, AVM/dAVF embolization, carotid and intracranial stenting, spine intervention, neurointerventional devices
+- **Open Access:** Hybrid (optional Gold OA with APC; subscription route free to authors)
+- **Language:** British English
+- **Peer Review:** Double-anonymised (author identifiers must be removed from the manuscript file)
+- **ORCID:** Mandatory for submitting author
+- **Acceptance / Timing (BMJ metrics — verify at submission):** approximately 18% acceptance; median first decision approximately 24 days
+
+---
+
+## Scope — Covered Topics
+
+- Acute ischemic stroke — mechanical thrombectomy, stentriever/aspiration, imaging selection
+- Intracranial aneurysm — coiling, stent-assisted coiling, flow diversion, intrasaccular devices
+- Arteriovenous malformation and dural arteriovenous fistula embolization
+- Carotid artery stenting, intracranial atherosclerotic disease stenting
+- Spine interventions (vertebroplasty, kyphoplasty, spinal angiography, embolization)
+- Neurointerventional device evaluation (first-in-human, post-market, registry)
+- Clot and plaque histology from endovascular retrieval
+- Socioeconomics, workforce, and systems of neurointerventional care
+
+---
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | Figures/Tables | References |
+|------|----------------|----------|----------------|------------|
+| Original Research | 3,500 | 250 (structured) | 4 | ≤30 |
+| Review | 4,000 | 250 (unstructured) | 4 | ≤60 |
+| Case Series | 2,500 | 250 (structured) | 4 | ≤20 |
+| Brief / Short Report | 2,000 | 200 (structured) | 2 | ≤15 |
+| Case Report | 800 | 150 (brief) | 2 | ≤10 |
+| Technical Note / New Device | 2,000 | 200 | 3 | ≤15 |
+| Editorial (invited) | 1,500 | None | 2 | ≤15 |
+| Letter / e-Letter | 600 | None | 1 | ≤5 |
+| Video Report | 500 + video | 150 | n/a | ≤10 |
+
+*Verify exact current limits on the author guidelines page before submission — BMJ periodically revises its limits.*
+
+---
+
+## Abstract Requirements
+
+**Structured 250-word abstract for Original Research:**
+
+```
+Background: [Clinical question; rationale]
+Methods: [Study design, population, interventions, outcomes, statistical approach]
+Results: [Key numerical results with effect sizes and 95% CI]
+Conclusions: [Main conclusion; clinical implication]
+```
+
+---
+
+## Key Messages Box (Mandatory for Original Research)
+
+A three-bullet summary box is required:
+
+```
+WHAT IS ALREADY KNOWN ON THIS TOPIC
+• [1–2 sentences on current knowledge]
+
+WHAT THIS STUDY ADDS
+• [1–2 sentences on the novel contribution]
+
+HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
+• [1–2 sentences on implications]
+```
+
+---
+
+## Domain-Specific Outcome Measures
+
+### For Acute Ischemic Stroke Thrombectomy
+
+- **Recanalization:** mTICI (modified Treatment in Cerebral Infarction) — report rates of mTICI 2b/2c/3 (successful reperfusion = 2b–3; excellent = 2c–3)
+- **Functional outcome at 90 days:** mRS (modified Rankin Scale); good outcome commonly mRS 0–2
+- **Symptomatic intracranial hemorrhage (sICH):** state definition used (ECASS II, ECASS III, SITS-MOST, NINDS, or Heidelberg)
+- **Procedure time:** puncture-to-reperfusion; onset-to-reperfusion when available
+- **Mortality at 90 days**
+- **First-pass effect (FPE):** mTICI 2c–3 after a single pass
+
+### For Aneurysm Treatment
+
+- **Angiographic occlusion:** Raymond-Roy Occlusion Classification (RROC) for coiling; O'Kelly–Marotta (OKM) scale for flow diverters
+- **Retreatment rate** with follow-up interval explicit
+- **Procedural complications:** thromboembolic events, intraprocedural rupture, access-site complications — pre-specify definitions
+- **Delayed ischemic events and delayed aneurysm rupture**
+
+### For AVM / dAVF Embolization
+
+- **Complete obliteration rate** on follow-up DSA
+- **Spetzler-Martin grade (AVM)** and **Cognard/Borden classification (dAVF)** for risk stratification
+- **Rehemorrhage rate** with follow-up interval explicit
+
+### Imaging / Device Studies
+
+- **Diagnostic accuracy:** sensitivity, specificity, AUC with 95% CI
+- **Inter-rater agreement:** Cohen's kappa or ICC
+- **Report reference standard** (DSA, surgical confirmation, multidisciplinary adjudication)
+
+---
+
+## Required Sections
+
+1. **Introduction** — Background; knowledge gap; specific aim
+2. **Methods**
+   - Ethics: IRB/ethics committee approval + informed consent statement (or waiver rationale)
+   - Study design, setting, participants, timeframe
+   - Exposures, interventions, and outcomes with explicit definitions
+   - Statistical analysis
+   - Reporting-guideline citation (STROBE/CONSORT/PRISMA/STARD/ARRIVE/TRIPOD)
+   - **Data Availability Statement — mandatory (BMJ Tier 3 policy)**
+3. **Results**
+   - Participant flow / baseline characteristics
+   - Primary and secondary outcomes with effect sizes and 95% CI
+   - Subgroup and sensitivity analyses
+4. **Discussion** — include Limitations subsection
+5. **Conclusion**
+
+---
+
+## Data Sharing Statement (BMJ Tier 3 — Mandatory)
+
+Every Original Research article must include a Data Availability Statement. Acceptable forms include (examples):
+- "Data are available in a public, open access repository at [URL/DOI]."
+- "Data are available upon reasonable request to the corresponding author."
+- "No data are available." (only when legally or ethically restricted — must justify)
+
+---
+
+## Reference Style
+
+- **Vancouver numbered system**
+- Superscript reference numbers in the text
+- List first 6 authors followed by "et al." when there are more than 6 authors (verify on BMJ reference style page)
+- Journal abbreviations per Index Medicus / NLM
+- Include DOI or PMID when available
+
+---
+
+## Statistical Reporting Expectations
+
+- Effect sizes with 95% CI — not p-values alone
+- State statistical software (name, version, key packages)
+- Time-to-event: Kaplan-Meier with log-rank; Cox regression with PH assumption check
+- Diagnostic accuracy: AUC with 95% CI (DeLong); sensitivity/specificity with Clopper-Pearson CI
+- Missing data: describe amount and handling (complete-case, multiple imputation, IPW)
+- Propensity-score and IPW methods: report covariates, balance diagnostics (standardized mean difference)
+
+---
+
+## Figures
+
+- High-resolution TIFF, EPS, or PDF (≥300 dpi for halftone; ≥600 dpi for line art)
+- Label panels with capital letters (A, B, C, ...)
+- Scale bars for radiographs/histology; anatomical orientation labels for angiograms
+- Figure legends separate from figures in the manuscript file
+- Video files supported for endovascular case material
+
+---
+
+## Peer Review Model — Double-Anonymised
+
+Authors must prepare the main manuscript file without:
+- Author names, affiliations, emails on the title page (submitted separately)
+- Acknowledgments, funding statements, or any wording that identifies the institution
+- Self-citations that reveal the group ("as we previously reported in reference X")
+
+Submit a separate title-page file with full authorship metadata.
+
+---
+
+## Common Rejection Reasons
+
+1. **Scope mismatch** — non-neurointerventional work; stroke medical therapy without endovascular component belongs in a stroke journal
+2. **Low sample size for single-center retrospective series** without external validation
+3. **Missing reporting-guideline checklist**
+4. **Vague outcome definitions** — mTICI, mRS cutoff, sICH, RROC/OKM all must be pre-specified and cited
+5. **Failure to strip identifying information** — returned for double-anonymization non-compliance
+6. **Missing or inadequate Data Availability Statement** (BMJ Tier 3 non-compliance)
+7. **Weak comparison to prior literature** — incremental reports of well-established techniques need a clear reason for publication
+
+---
+
+## Author Guidelines URL
+
+https://jnis.bmj.com/pages/authors/
+
+---
+
+## AI Writing Disclosure Policy
+
+JNIS follows BMJ's generative-AI policy and ICMJE recommendations:
+
+1. **AI cannot be an author** (ICMJE) — AI tools cannot take responsibility for the work.
+2. **Disclose substantive AI use** in Methods (when used in research design, analysis, or drafting specific text) and in the Acknowledgments.
+3. **AI-generated references are prohibited** — the corresponding author is responsible for all citation accuracy.
+4. **Basic grammar / spell-check tools** (e.g., Grammarly, word-processor spell-check) do not require disclosure.
+5. **Generative-AI image creation or manipulation is prohibited** in scientific figures (angiograms, histology, MRI, CT).
+6. **Prompt transparency:** when AI is used in data analysis or figure generation, provide sufficient detail (prompts, tool version) for reproducibility.
+
+Always re-check the BMJ and JNIS author pages at submission for updates.
+
+---
+
+## Positioning
+
+JNIS is appropriate when:
+- The study is primarily endovascular or surgical neurointerventional in nature
+- The endpoint includes procedural success (mTICI, RROC, OKM), device performance, or technical complication rates
+- Target audience includes interventional neuroradiologists, endovascular neurosurgeons, and interventional neurologists
+- First-in-human device studies, registry reports, and technical notes are welcome
+
+JNIS is less appropriate for: medical (non-endovascular) stroke management (consider Stroke or Journal of Stroke), purely imaging-diagnostic work without intervention (consider AJNR, Neuroradiology), or basic cerebrovascular biology (consider Stroke basic/translational track or ATVB).
+
+---
+
+## Verification note
+
+Profile built 2026-04-19 from the JNIS author guidelines PDF (https://jnis.bmj.com/pages/authors/). BMJ Tier 3 data-sharing policy, double-anonymised review model, ORCID mandate, and Key Messages box requirement are transcribed from the same source. Acceptance-rate and first-decision timing figures are the BMJ-reported values on the authors page; re-verify at submission.

package/skills/write-paper/references/journal_profiles/JVIR.md

@@ -0,0 +1,158 @@
+# Journal Profile: Journal of Vascular and Interventional Radiology (JVIR)
+
+## Journal Identity
+
+- **Full name**: Journal of Vascular and Interventional Radiology
+- **Abbreviation**: J Vasc Interv Radiol
+- **Publisher**: Elsevier (SIR — Society of Interventional Radiology)
+- **ISSN**: 1051-0443 (print), 1535-7732 (online)
+- **Frequency**: Monthly (12 issues/year)
+- **Impact Factor**: ~3.5 (JCR 2023)
+- **Open Access**: Hybrid (optional OA with Elsevier APC)
+- **Acceptance rate**: ~25%
+- **Peer review**: Single-blind; 2-3 reviewers per manuscript
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Clinical Investigation | 3000 words | 250 words (structured) | 35 | 6 |
+| Clinical Practice | 3000 words | 250 words | 35 | 6 |
+| Technical Report | 2000 words | 150 words (unstructured) | 20 | 4 |
+| Case Report | 1500 words | 100 words (unstructured) | 10 | 4 |
+| Review Article | 4000 words | 250 words | 75 | 8 |
+| Systematic Review / Meta-Analysis | 4000 words | 250 words (structured) | 60 | 8 |
+| Letter to the Editor | 500 words | None | 5 | 1 |
+
+Word counts exclude abstract, references, tables, and figure legends.
+
+---
+
+## Abstract Requirements
+
+**Structured abstract for Clinical Investigations and SRMAs, 250 words maximum:**
+
+```
+Purpose: [Study aim]
+Materials and Methods: [Design, setting, population, intervention, outcomes,
+    statistical analysis]
+Results: [Key findings with statistics]
+Conclusions: [Main conclusion — 1-2 sentences]
+```
+
+**Unstructured abstract for Technical Reports, 150 words. Case Reports, 100 words.**
+
+---
+
+## Required Sections (Clinical Investigation)
+
+1. **Introduction** — clinical context, knowledge gap, study purpose (2-3 paragraphs)
+2. **Materials and Methods**
+   - Study Design and Oversight: IRB, retrospective/prospective
+   - Patient Selection: inclusion/exclusion, time period
+   - Procedure: step-by-step technical description with device details
+   - Endpoints: primary and secondary, with definitions
+   - Follow-up Protocol: imaging and clinical assessment schedule
+   - Statistical Analysis: software, methods, significance level
+3. **Results** — demographics, procedural data, primary outcomes, secondary outcomes, complications
+4. **Discussion** — findings in context, comparison with literature, limitations
+5. **Conclusions**
+
+---
+
+## Statistical Reporting
+
+- Report exact p-values; use p < .001 below that threshold.
+- 95% CI for all primary outcomes.
+- Technical and clinical success rates with exact denominators (n/N, %).
+- Complication rates per SIR classification (mandatory for IR studies).
+- For time-to-event: Kaplan-Meier with log-rank test; report median and 95% CI.
+- Multivariate analysis: report adjusted OR/HR with 95% CI.
+- For meta-analyses: heterogeneity (I-squared, Q-test), publication bias assessment.
+- Report per-patient AND per-procedure rates when they differ.
+- Statistical software and version must be identified.
+
+---
+
+## IR-Specific Requirements
+
+### SIR Complication Classification (Mandatory)
+
+JVIR, as the SIR journal, strictly enforces SIR complication classification:
+- **Minor complications**: A (no therapy required), B (nominal therapy)
+- **Major complications**: C (requires therapy, minor hospitalization), D (major therapy, escalation of care), E (permanent adverse sequelae), F (death)
+
+### Outcome Definitions
+
+Must explicitly define:
+- **Technical success**: procedure-specific (e.g., "complete tumor coverage on immediate post-ablation imaging")
+- **Clinical success**: patient-centered (e.g., "symptom resolution or improvement at 30 days")
+- **Primary/assisted-primary/secondary patency** (vascular)
+- **Local tumor progression-free survival** (ablation/embolization)
+
+### Device Reporting
+
+Manufacturer name, device model, and configuration for all devices. JVIR readership is procedurally oriented and expects reproducible technical detail.
+
+---
+
+## Figures
+
+- **Maximum 6 figures/tables combined** for clinical investigations
+- **Resolution**: 300 DPI minimum (600 DPI for line art)
+- **Format**: TIFF, EPS, PDF
+- **Color**: Free online
+- **Typical figure set**: patient selection flowchart, pre-/intra-/post-procedure images, outcome graphs (Kaplan-Meier, bar charts)
+
+---
+
+## Common Rejection Reasons
+
+1. **Retrospective single-center with small N and no novelty** — JVIR receives many of these
+2. **Missing SIR complication classification** — mandatory for the society's journal
+3. **Undefined technical/clinical success** — must be pre-specified
+4. **Inadequate follow-up** — ablation studies need minimum 6-12 months imaging follow-up
+5. **No comparative group** — single-arm studies need strong justification
+6. **Duplicate scope with CVIR submission** — JVIR and CVIR do not share reviews; dual submission detected via reviewer overlap
+
+---
+
+## Cover Letter
+
+Should include:
+- Relevance to SIR members and IR practice
+- Statement of novelty
+- Brief summary of key finding
+- Suggested reviewers (3+) with expertise in the specific IR subspecialty
+
+---
+
+## Author Guidelines URL
+
+https://www.jvir.org/content/authorinfo
+
+---
+
+## Positioning
+
+JVIR is appropriate when:
+- Interventional radiology clinical investigation with adequate sample size
+- IR technique innovation with clinical outcome data
+- Systematic review or meta-analysis of IR procedures
+- Quality improvement or practice pattern study in IR
+- Multi-center IR study (especially US-based centers)
+
+Not appropriate for: diagnostic imaging without intervention, non-IR procedures, pure imaging methodology.
+
+---
+
+## Differentiation from CVIR
+
+| Dimension | JVIR | CVIR |
+|-----------|------|------|
+| Society | SIR (American) | CIRSE (European) |
+| Geography emphasis | North American and international | European and international |
+| Impact factor | ~3.5 | ~3.0 |
+| Complication standard | SIR classification (strict) | SIR or Clavien-Dindo |
+| Article types | Clinical Investigation / Practice | Original Article |
+| Thematic issues | Quality improvement, standards of practice | Less common |

package/skills/write-paper/references/journal_profiles/Journal_of_Clinical_Endocrinology_and_Metabolism.md

@@ -0,0 +1,191 @@
+# Journal Profile: The Journal of Clinical Endocrinology & Metabolism (JCEM)
+
+## Journal Identity
+
+- **Full name**: The Journal of Clinical Endocrinology & Metabolism
+- **Abbreviation**: J Clin Endocrinol Metab
+- **Publisher**: Oxford University Press (on behalf of the Endocrine Society)
+- **ISSN**: 0021-972X (print) / 1945-7197 (online)
+- **Frequency**: Monthly
+- **Impact Factor**: ~5.8 (recent JCR; verify at submission)
+- **Open Access**: Hybrid — page-charge model (USD 99–119 per PDF page, member vs non-member; color figure surcharge USD 235–735); separate Gold OA option via OUP open-access portal
+- **Peer review**: Single-blind; methodology-heavy submissions may receive statistical or sub-specialty review
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Clinical Research Article (Original) | not stated as a hard cap | 250 (structured, complete sentences) | not stated | not stated |
+| Approach to the Patient | 2,000–5,000 words | 150–250 | varies | varies |
+| Mini-review | 2,000–5,000 words | 150–250 | varies | varies |
+| Meta-analysis | as Original | as Original | as Original | as Original |
+| Editorial | 1,500 words | none | 15 max | 1 max |
+| Commentary | 1,500 words | none | 15 max | 1 max |
+| Letter to the Editor | 500 words | none | 5 max | 1 max |
+| Report and Recommendation | per society/consensus | varies | varies | varies |
+
+JCEM does not enforce a numeric upper word limit on Original (Clinical Research Article) submissions; tight scientific writing is expected, and editors will request trimming at the revision stage if the manuscript runs long.
+
+---
+
+## Abstract Requirements
+
+**Structured abstract, 250 words maximum, in complete sentences:**
+
+```
+Purpose / Context: [Specific scientific question and clinical relevance]
+Methods: [Design, setting, population, exposures, outcomes, statistical approach]
+Results: [Primary results with effect sizes, 95% CIs, P values; N analyzed]
+Main Conclusion: [Direct answer to Purpose with clinical implication]
+```
+
+JCEM requires the abstract to be written in **complete sentences without direct text references** (no "(Figure 1)" or "(Table 2)" pointers). The four sections (Purpose, Methods, Results, Main Conclusion) are the canonical structure.
+
+---
+
+## Required Journal-Specific Elements
+
+### 1. Précis (Key Message)
+
+One-sentence summary (≤30 words) of the principal finding, requested at submission. Used by editors and the Endocrine Society newsroom; do not skip.
+
+### 2. Article Information
+
+- Author affiliations with department, institution, city, country
+- Corresponding author full contact details
+- Funding statement with grant identifiers
+- Disclosures: per-author ICMJE conflicts
+- Data availability statement
+- Ethical statement (IRB or equivalent + informed consent)
+
+### 3. Submission File Requirements
+
+JCEM asks authors to **list all authors at the initial submission** (no first-N-then-et-al truncation in references at submission stage). The Endocrine Society uses the full author list for editorial workflow and indexing decisions.
+
+---
+
+## Required Sections (Original Article)
+
+1. **Introduction** — concise (2–3 paragraphs) ending with clear purpose
+2. **Materials and Methods** (JCEM convention)
+   - Ethics approval with body name
+   - Study design and setting
+   - Participants and eligibility
+   - Variables / definitions with assay details (intra-/inter-assay CV for hormone measurements)
+   - Outcomes (primary, secondary, exploratory clearly distinguished)
+   - Statistical analysis with software and versions
+3. **Results** — flow diagram for cohort selection; primary outcome before secondary
+4. **Discussion** — Strengths and Limitations sub-paragraphs; conclude with endocrine-mechanism implications and clinical translation
+5. **Main Conclusion** — brief; avoid overclaiming
+
+---
+
+## Statistical Reporting
+
+- Exact P values to 3 decimal places (P < 0.001 below threshold)
+- 95% CI for all primary effect estimates
+- Effect sizes appropriate to design (HR, OR, mean difference, beta coefficient)
+- For hormonal axes: report assay platform, reference range, and within-subject coefficient of variation
+- Proportional-hazards assumption check (Schoenfeld) when Cox is used
+- Sensitivity analyses for major analytic choices
+- Software and version reported
+
+---
+
+## Figures
+
+- Color figure surcharge: USD 235–735 per figure (verify current schedule)
+- Resolution: 300 DPI minimum
+- Format: TIFF, EPS, PDF
+- Supplementary material: online-only supplement permitted
+
+---
+
+## Common Rejection Reasons
+
+1. **Insufficient endocrine-mechanism contribution** — clinical observations without hormonal-axis or metabolic-mechanism framing are redirected
+2. **Single-center cohort without external comparison** — population-based or multicenter preferred
+3. **Missing assay validation** — methodology bar is high for hormonal and metabolic biomarkers
+4. **Overclaiming on observational data** — wide-CI estimates without exploratory qualifier
+5. **Abstract style violation** — not using complete sentences or including direct text references
+6. **AI policy non-compliance** — undisclosed AI use or AI listed as author
+7. **Reference list incomplete at submission** — submitting with truncated author lists or missing references
+
+---
+
+## Cover Letter
+
+Must include:
+- Brief statement of novelty and clinical-endocrine relevance
+- Précis (≤30 words) of principal finding
+- Confirmation manuscript is not under consideration elsewhere
+- Confirmation all authors meet ICMJE criteria
+- Disclosure of related manuscripts (same cohort, same group)
+- Suggested reviewers (3–5; senior PI curates)
+- AI disclosure aligned with in-manuscript declaration
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level**: Required
+- **Verbatim policy**: "The use of artificial intelligence (AI) tools must be disclosed during the submission process and also described in the Methods or Acknowledgments sections of the text."
+- **Disclosure location**: Both the submission portal disclosure step AND the Methods or Acknowledgments section
+- **Reviewer restriction**: Reviewers are explicitly prohibited from uploading any part of a manuscript into LLM tools during review (confidentiality)
+- **AI-generated images**: Covered by the general disclosure; not separately permitted
+- **Policy URL**: https://academic.oup.com/jcem/pages/Author_Guidelines
+
+---
+
+## Submission Portal
+
+https://www.editorialmanager.com/jcem/
+
+---
+
+## Author Guidelines URL
+
+https://academic.oup.com/jcem/pages/Author_Guidelines
+
+---
+
+## Positioning
+
+| Criterion | JCEM | Endocrinology and Metabolism (EnM) | Diabetes & Metabolism Journal (DMJ) | Diabetes Care |
+|-----------|------|------------------------------------|-------------------------------------|---------------|
+| **Society** | Endocrine Society (global) | Korean Endocrine Society | Korean Diabetes Association | American Diabetes Association |
+| **Impact Factor** | ~5.8 | ~3.5 | ~5.5 | ~16 |
+| **Open Access** | Hybrid (page-charge default) | Full OA | Full OA (CC BY-NC) | Hybrid |
+| **Geographic stance** | Global | Korean / East Asian | Korean / East Asian | Global, US-centric |
+| **Primary framing** | Clinical endocrinology / metabolism — broad axis | Endocrinology, hormonal-axis focused | Diabetes / metabolism focused | Type 2 diabetes, clinically driven |
+| **Abstract style** | 4-section (Purpose/Methods/Results/Main Conclusion), complete sentences | 4-heading (Background/Methods/Results/Conclusion) | 4-heading (Background/Methods/Results/Conclusion) | 4-heading (Objective/Research Design/Results/Conclusions) |
+| **Word cap (Original)** | not stated | 4,000 | 4,000 | varies |
+| **AI policy** | Submission portal + Methods/Acknowledgments | Manuscript + cover letter | Title page | Methods + Acknowledgments |
+
+**Choose JCEM when:**
+- Endocrine-mechanism framing is the primary scientific contribution
+- Clinical-endocrine community visibility (Endocrine Society) matters
+- Hormonal-axis or metabolic-axis pathway is the central narrative
+- Manuscript can support the implicit "high methodological rigor" bar without a hard word cap
+
+**Choose Endocrinology and Metabolism (KES) instead when:**
+- Korean / East Asian population cohort with regional-relevance framing
+- Lower IF threshold acceptable in exchange for faster decision (≤3 months)
+
+**Choose DMJ instead when:**
+- Diabetes-specific framing dominates over broader endocrinology
+- Korean Diabetes Association ecosystem visibility matters
+
+**Choose Diabetes Care instead when:**
+- T2DM clinical-practice impact is the dominant framing
+- Higher IF requirement (e.g., for promotion)
+- Global, US-centric audience matters more than endocrine-society fit
+
+---
+
+## Verification
+
+- **Source (compact harvest):** local private profile (2026-05-20 fetch from https://academic.oup.com/jcem/pages/Author_Guidelines)
+- **Source (detail authored):** based on harvested compact + JCEM verbatim AI policy + OUP/Endocrine Society standard practice
+- **Date (promoted to public):** 2026-05-21
+- **Notes:** No upper word limit for Original at submission; editors may request trimming during revision. Verify page-charge and color-figure surcharge directly at OUP.